Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Et forsøk for å vurdere Cobicistat forsterket Venetoclax i kombinasjon med azacitidin hos voksne pasienter med nylig diagnostisert AML (HO171)

En enkeltarms fase II-forsøk for å vurdere kobicistat-forsterket venetoklaks i kombinasjon med azacitidin (sc) hos voksne pasienter med nylig diagnostisert akutt myeloid leukemi (AML) som ikke anses som kandidater for intensive behandlingsregimer

The treatment of older unfit patients with acute myeloid leukemia (AML) is challenging. The hypomethylating agents (HMA) azacitidine and decitabine have relatively mild side effects and have proven to be feasible for the treatment of older patients and patients with co-morbidities. Currently, venetoclax added to an HMA agent is the new standard of treatment. Since this new standard comes with a substantial societal financial burden, there is a rational to optimize the venetoclax dosing schedule. The CYP3A4 inhibitor cobicistat (COBI) can be used to increase venetoclax exposure, thereby allowing to reduce the dose of venetoclax and thus costs substantially.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

142

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

  • Navn: Gerwin Huls, prof
  • Telefonnummer: +3150 361 2354
  • E-post: g.huls@umcg.nl

Studiesteder

      • 's-Hertogenbosch, Nederland
        • Rekruttering
        • NL-Den Bosch-JBZ
        • Ta kontakt med:
          • A.H.E. Herbers, Dr.
      • Amersfoort, Nederland
        • Rekruttering
        • NL-Amersfoort-MEANDERMC
        • Ta kontakt med:
          • M.F. Corsten, Dr.
      • Amsterdam, Nederland
        • Rekruttering
        • NL-Amsterdam-OLVG
        • Ta kontakt med:
          • H. Mooij, Dr.
      • Amsterdam, Nederland
        • Rekruttering
        • NL-Amsterdam-AUMC
        • Ta kontakt med:
          • C. Alhan, Dr.
      • Arnhem, Nederland
        • Rekruttering
        • NL-Arnhem-RIJNSTATE
        • Ta kontakt med:
          • M.L.H. Cuijpers, Dr.
      • Breda, Nederland
        • Rekruttering
        • NL-Breda-AMPHIA
        • Ta kontakt med:
          • R.B. Fiets, Dr.
      • Dordrecht, Nederland
        • Rekruttering
        • NL-Dordrecht-ASZ
        • Ta kontakt med:
          • P.E. Westerweel, Dr.
      • Eindhoven, Nederland
        • Rekruttering
        • NL-Eindhoven-MAXIMAMC
        • Ta kontakt med:
          • L.W. Tick, Dr.
      • Eindhoven, Nederland
        • Rekruttering
        • NL-Eindhoven-CATHARINA
        • Ta kontakt med:
          • M.J. Cruijsen, Dr.
      • Enschede, Nederland
        • Rekruttering
        • NL-Enschede-MST
        • Ta kontakt med:
          • T.J.F. Snijders, Dr.
      • Groningen, Nederland
        • Rekruttering
        • NL-Groningen-UMCG
        • Ta kontakt med:
          • G.A. Huls, Prof. dr.
      • Leeuwarden, Nederland
        • Rekruttering
        • NL-Leeuwarden-MCL
        • Ta kontakt med:
          • B. Franken, Dr.
      • Leiden, Nederland
        • Rekruttering
        • NL-Leiden-LUMC
        • Ta kontakt med:
          • P.A. von dem Borne, Dr.
      • Maastricht, Nederland
        • Rekruttering
        • NL-Maastricht-MUMC
        • Ta kontakt med:
          • C.H.M.J. van Elssen, Dr.
      • Nieuwegein, Nederland
        • Rekruttering
        • NL-Nieuwegein-ANTONIUS
        • Ta kontakt med:
          • O. de Weerdt, Dr.
      • Nijmegen, Nederland
        • Rekruttering
        • NL-Nijmegen-RADBOUDUMC
        • Ta kontakt med:
          • N.A. de Jonge, Dr.
      • Nijmegen, Nederland
        • Rekruttering
        • NL-Nijmegen-CWZ
        • Ta kontakt med:
          • S. de Jonge, Dr.
      • The Hague, Nederland
        • Rekruttering
        • NL-Den Haag-HAGA
        • Ta kontakt med:
          • D. van Lammeren, Dr.
      • Zwolle, Nederland
        • Rekruttering
        • NL-Zwolle-ISALA
        • Ta kontakt med:
          • T.T. de Waal, Dr.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

In order to be eligible to participate in this study, a patient must meet all of the following criteria:

  • Patients with: a diagnosis of AML and related precursor neoplasms according to ICC-2022 classification (excluding acute promyelocytic leukaemia) (appendix A). Patients may have had previous treatment with erythropoiesis stimulating agents (ESA) for an antecedent phase of MDS. ESAs must be stopped at least two weeks before registration.

  • Patients 18 years and older who are considered not fit for intensive chemotherapy or who decline the option of intensive chemotherapy.

  • WHO performance status 0, 1 or 2 (appendix E).

  • Leukocytes < 30 x109/L

  • Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values:

    • Adequate renal function as demonstrated by a creatinine clearance ≥ 30 mL/min; calculated by the Cockcroft Gault formula or measured by 24 hours urine collection.
    • Serum bilirubin ≤ 3 x upper limit of normal (ULN), unless considered AML-related or due to Gilbert's syndrome.
    • Alanine transaminase (ALT) ≤ 3 x ULN, unless considered AML-related.
  • Male subjects who are sexually active, must agree, from Study Day 1 until at least 90 days after the last dose of study drug, to practice the protocol specified contraception. Male subjects must agree to refrain from sperm donation from initial study drug administration through at least 90 days after the last dose of study drug.

  • Female subjects must be either postmenopausal defined as: Age >55 years with no menses for ≥12 months, without an alternative medical cause. OR willing and able to use adequate contraception during and until 180 days after the last protocol treatment.

  • Written informed consent.

  • Patient is capable of giving informed consent.

  • Patient agrees not to participate in another interventional study while on treatment without approval of the (co-) Principal Investigator.

Exclusion Criteria:

A patient who meets any of the following criteria cannot be included in this study:

  • Acute promyelocytic leukemia.

  • Myelodysplastic syndrome (MDS).

  • Patients previously treated for AML or MDS (any anti-leukemic therapy including investigational agents; excluding: 1) erythropoiesis stimulating agents (ESAs); 2) hydroxyurea ((previous treatment with hydroxyurea is allowed for the control of peripheral leukemic blasts in patients with leukocytosis).

  • Diagnosis of any previous or concomitant malignancy is an exclusion criterion:

    • except when the patient successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 24 months prior to registration;
    • except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix.
  • Blast crisis of chronic myeloid leukemia.

  • Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.).

  • Cardiac dysfunction as defined by:

    • Myocardial infarction within the last 3 months of study entry, or
    • Reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram, or
    • Unstable angina or New York Heart Association (NYHA) grade IV congestive heart failure (see Appendix G), or
    • Unstable cardiac arrhythmias.
  • History of stroke or intracranial haemorrhage within 6 months prior to registration.

  • Symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement).

  • History of non-compliance to medical regimens or considered unreliable with respect to compliance.

  • Senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.

  • Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea.

  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.

  • Unreplaceable use of strong inhibitors or inducers of CYP3A or CYP3A/p-GP substrates with a narrow therapeutic window (e.g. cobicistat or ritonavir for HIV treatment). Please check with Appendix I.

  • Intolerability, contra-indication or allergy to one of the study drugs.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Sekvensiell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: single arm arm extension phase

prior to the extention phase, there is a run-in phase with (n= 20 patients of 142 total) with the same study scheme, except that cobicistat is added from cycle 2 onwards to the treatment instead of during cycle 1

during run-in and extention phase: from Cycle 1 until relapse

during run-in and extention phase: from Cycle 1 until relapse

during run-in phase: from cycle 2 until relapse

during extension phase: from cycle 1 until relapse

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Pharmacokinetic equivalence of cobicistat boosted venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).venetoclax and unboosted venetoclax (PK cycle 1 vs PK cycle 2).
Tidsramme: 6-8 months

run-in phase

6-8 months
Overall survival (OS).
Tidsramme: 48 months

extension phase

48 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Venetoclax and cobicistat CL, Cmax, Tmax, Cmin and AUC0-24.
Tidsramme: 6-8 months

run-in phase

6-8 months
Complete remission (CR) rate defined as CR as best response during or at completion of the treatment, as determined by the Investigator, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsramme: 48 months

extension phase

48 months
CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsramme: 48 months

extension phase

48 months
CR and CR with incomplete hematologic recovery (CRi) rate, based on the European LeukemiaNet (ELN2022) recommended response criteria (see Appendix B).
Tidsramme: 48 months

extension phase

48 months
CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Tidsramme: 48 months

extension phase

48 months
CR and CR with partial hematologic recovery (CRh) rate, based on ELN 2022 recommendations.
Tidsramme: 48 months

extension phase

48 months
CR or CR/CRi or CR/CRh without minimal residual disease (flow and or molecular) (CRMRD- or CR/CRiMRD- or CR/CRhMRD-).
Tidsramme: 48 months

extension phase

48 months
Morphologic leukemia-free state (MLFS) rate, based on ELN2022 recommendations.
Tidsramme: 48 months

extension phase

48 months
Event free survival (EFS).
Tidsramme: 48 months

extension phase

48 months
Relapse-free survival (RFS).
Tidsramme: 48 months

extension phase

48 months
Incidence and severity of adverse events according to CTCAE version 5.0.
Tidsramme: 48 months

extension phase

48 months
Early (30-day and 60-day) mortality (in general, non-leukemic).
Tidsramme: 48 months

extension phase

48 months
Time to next cycle, defined as the time from the start of the cycle until the start of the next cycle.
Tidsramme: 48 months

extension phase

48 months
OS of AZA/VEN/COBI treated patients in comparison with a real-world data cohort treated during the same time period and monitored by the Dutch Cancer registry.
Tidsramme: 48 months

extension phase

48 months
Prognostic/predictive impact of disease-associated genetic changes at diagnosis.
Tidsramme: 48 months

extension phase

48 months
Relapse-associated genetic changes (determined at relapse). The average relative dose intensity will be computed and given by categories. The same will be done for treatment deviation.
Tidsramme: 48 months

extension phase

48 months
Clonal evolution during treatment.
Tidsramme: 48 months

extension phase

48 months
Exposure-response and exposure-toxicity relation of venetoclax in patients with AML.
Tidsramme: 48 months

extension phase

48 months
Cost-savings on venetoclax drug costs.
Tidsramme: 48 months

extension phase

48 months
Adherence to venetoclax and cobicistat.
Tidsramme: 48 months

extension phase

48 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. januar 2024

Primær fullføring (Antatt)

1. desember 2028

Studiet fullført (Antatt)

1. desember 2028

Datoer for studieregistrering

Først innsendt

4. juli 2023

Først innsendt som oppfylte QC-kriteriene

23. august 2023

Først lagt ut (Faktiske)

28. august 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • HO171
  • 2023 (U.S. NIH-stipend/kontrakt)
  • 2023-505379-61-00 (Ctis)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .